The NFL’s Odell Beckham Jr. Just Became A New Face Of Dermatology
Odell Beckham Jr. (OBJ) and his dermatologist discuss his experience with seb derm, or seborrheic dermatitis, as the Wide ...
It's Only February and Odell Beckham Jr. Is Already Having Quite The Beauty Year
The football star got real with Cosmo about his recent experience with seborrheic dermatitis and so much more.
NFL Star Odell Beckham Jr. Opens Up About Chronic Skin Condition for the First Time
Odell Beckham Jr. opened up about his health and a recent diagnosis. “When I found out millions of others had this condition, ...
Arcutis Biotherapeutics' senior VP Matsuda sells $105,892 in stock
Matsuda Masaru, Senior Vice President at Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), recently sold shares of the company's ...
Arcutis director Howard G. Welgus sells $127,100 in common stock
In a recent transaction, Howard G. Welgus, a director at Arcutis Biotherapeutics Inc . (NASDAQ:ARQT), sold 10,000 shares of the company's common stock. The shares were sold at a weighted average price ...
Odell Beckham Jr. Recalls Struggling with 'Uncomfortable’ Skin Disease: ‘I Really Wanted to Figure It Out’ (Exclusive)
Odell Beckham Jr. opens up to PEOPLE exclusively about being diagnosed with seborrheic dermatitis, a chronic skin disease, ...
Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a "Clear Win for Your Skin"
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful ...
Odell Beckham Jr. Reveals He's Been Dealing With a Skin Condition for Years — How He Finally Found Relief (Exclusive)
At first it was mild, and then it started to get a lot worse,' the athlete exclusively tells Parade of his chronic skin ...
FiercePharma1d
Arcutis drafts NFL star Odell Beckham Jr. to raise awareness of seborrheic dermatitis, Zoryve treatment
Arcutis Biotherapeutics is going long with the latest push for its seborrheic dermatitis treatment Zoryve. | Arcutis ...
Positive Outlook for Arcutis Biotherapeutics Despite Temporary Prescription Declines
Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on January 29.Maximize Your Portfolio ...